Abstract: MATH/CHEM/COMP 2002, Dubrovnik, June 24-29, 2002
LATANOPROST MONOTHERAPY IS EFFECTIVE ANTIGLAUCOMA TREATMENT FOR
PATIENTS RESISTANT TO β-BLOCKERS
Nikola stambuk1, Josip Pavan2, Paško Konjevoda1, and Doroteja Pavan3
1Rudjer Boskovic Institute, POB 180, HR-10002 Zagreb, Croatia
2Clinical Hospital Dubrava, Avenija Gojka Suska bb, HR-10000 Zagreb, Croatia
3General Hospital Karlovac, Andrije Stampara 3, HR-47000 Karlovac, Croatia
Glaucoma is a major global cause of blindness. Its prevalence varies between countries and increases with age. Latanoprost (PhXA41) is a prostaglandin analogue which has a novel mechanism of action on intraocular pressure. We analysed ocular hypotensive efficacy of latanoprost (XalatanŇ), in a clinical trial conducted on 157 patients. XalatanŇ is a topical solution containing latanoprost 0.005% as the active ingredient. The results of the study indicate that latanoprost (XalatanŇ) may be an useful therapeutic agent in glaucoma patients resistant to beta-blockers. Chemistry, biochemistry and modes of action of latanoprost will be discussed.